Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 83 Matches

Pyronaridine

Model Files Publication

Brand Name(s) include: Pyramax

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related files: Artesunate (fixed dose combination – Pyramax)

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 3) Note: Kp scalar used
Route of Elimination	CYP1A2, CYP2B6, CYP2C8, CYP2D6 and CYP3A4
Perpetrator DDI	CYP2D6 Inhibitor P-gp Inhibitor
Validation	Two clinical studies describing pyronaridine exposure were available for model verification. 100% of predicted Cmax were within 1.5-fold of those observed whereas 40% of AUC were predicted within 1.5-fold of observed. This can be explained as observed exposure at 9mg/kg dose was lower than at 6 mg/kg. The model recovered the observed data at the 6 mg/kg dose but then over predicted that at the higher dose.
Limitations	One challenge in the verification of the model is the diverse ethnicities of subjects in reported clinical data and how best to reflect this in simulations. In the absence of virtual Korean populations within the Simulator, the Caucasian population was modified in terms of bodyweight. In the absence of supporting information, no changes to enzyme abundance (pmol/mg) were made to the population, although changes to liver weight (as a function of body weight) and hence total CYP abundance were propagated into the model.
Updates in V19	Switched to Method 3 to facilitate like for like comparisons for covid- 19 repurposing strategies

Search Score: 1

Oseltamivir_Carboxylate_V12R1_USFDA_20150709

Model Files Publication

Metabolite of oseltamivir. Information can be found in Table 1 and supplemental file of the publication. Table 1. also in supplemental file. Correction: Molecular weight should be 284 g/mol (in cmp file). Table 1 mistakenly listed MW of prodrug oseltamivir. Correction will be submitted to journal. The submitted cmp file has custom dosing. Oral dosing should be selected and dose should be adjusted according to MW differences between OC and prodrug oseltamivir to allow OC PK to be simulated when prodrug is given intravenously.

Search Score: 1

Darunavir&Ritonavir_V13R2_USFDA_20190719

Model Files Publication

Compound files from publication: Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir Wagner, C., Zhao, P., Arya, V., Mullick, C., Struble, K. and Au, S (2017). https://doi.org/10.1002/jcph.936 /PMID: 28569994 These two files were used in combination (linked models). Note: Darunavir model also has fu,mic for DDI, and induction parameters for CYP1A that were not captured in Supplemental Table 1. Correction: Ritonavir's pKa2 should be 2.6 instead of 2.8 in Suppl. Table 1. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.936

Search Score: 1

Dabigatran&DabigatranEtexilate_V17R1_UniversityOfTsukuba_20190204

Model Files Publication

Dabigatran etexilate and dabigatran compound files. Assessment of potential DDIs with P-gp inhibitors in renal impairment populations. https://www.ncbi.nlm.nih.gov/pubmed/30659778 https://doi.org/10.1002/psp4.12382

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Pyronaridine

The model at-a-glance

Oseltamivir_Carboxylate_V12R1_USFDA_20150709

Darunavir&Ritonavir_V13R2_USFDA_20190719

Dabigatran&DabigatranEtexilate_V17R1_UniversityOfTsukuba_20190204

Your Privacy